Too Many Avoidable Suicides Occur Worldwide in Young Patients

Area of Science:

• Pharmacology and regulatory science
• Pediatric drug development
• Mental health research

Background:

• US and EU laws aim to prevent discrimination against children in drug development.
• Pediatric studies on antidepressants resulted in a FDA black-box warning for suicidality in young patients.
• This warning created a conflict between patient safety and the need for adequate treatment for young depressed individuals.

Purpose of the Study:

• To analyze the history and impact of pediatric drug laws and studies.
• To examine the regulatory definitions and physiological realities of pediatric patients.
• To evaluate the medical validity and ethical implications of pediatric drug trials, particularly in psychiatry.

Main Methods:

• Historical analysis of drug development and disease perception in young patients.
• Review of US/EU pediatric laws and regulatory agency (FDA/EMA) requirements.
• Literature review on developmental pharmacology, financial interests, and pediatric studies in depression and other diseases.

Main Results:

• Regulatory definitions of pediatric patients (<17/18 years) are administrative, not physiological.
• Many "pediatric" studies, including those for depression, lack medical justification and can harm patients through placebo use.
• The US FDA has reduced separate pediatric efficacy studies, but not in psychiatry.

Conclusions:

• The concept of separate pediatric drug approval, especially in psychiatry, is flawed and should be abandoned.
• Clinicians, ethics committees, and regulatory bodies must critically re-evaluate existing and proposed pediatric studies.
• There is a need to prioritize evidence-based treatment over potentially harmful regulatory requirements for pediatric drug approval.